Merck Achieves Positive Results In Phase 3 Trial In Patients With Melanoma
March 25, 2015 at 21:00 PM EDT
In addition to releasing its phase 3 results for Keytruda, the company announced a $10 billion share repurchase program. Neither piece of news seems to be having much impact on share price.
